磷脂化重组人铜锌超氧化物歧化酶(Beijing Tide Pharmaceutical)(PC-SOD) - 药物靶点：SOD1_在研适应症：心肌再灌注损伤_专利_临床

概要

基本信息

药物类型

酶

别名

CY

靶点

SOD1

作用方式

调节剂

作用机制

SOD1调节剂(超氧化物歧化酶调节剂)

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

非在研机构-

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)临床2期

特殊审评-

登录后查看时间轴

关联

7

项与磷脂化重组人铜锌超氧化物歧化酶(Beijing Tide Pharmaceutical) 相关的临床试验

JPRN-jRCT2031210466

/ Completed临床2期IIT

Placebo-controlled, double-blind, randomized phase II study of PC-SOD for chemotherapy-induced peripheral neuropathy

开始日期2022-01-19

申办/合作机构-

NCT03995732

/ Unknown status临床2期

Efficacy and Safety Evaluation of Phosphatidyl Choline Cu/Zn Superoxide Dismutase (PC-SOD) for Injection in Reducing Myocardial Reperfusion Injury: a Multicenter, Randomized, Single-blind, Placebo-controlled Dose-finding Study

The current study aims to evaluate different doses of PC-SOD injections for efficacy and safety in comparison to placebo, in order to provide a basis for future clinical trials in terms of experimental design and dose selection.

开始日期2019-06-18

申办/合作机构

北京泰德制药股份有限公司

[+1]

CTR20160765

/ Completed临床1期

CY单中心、随机双盲、安慰剂平行对照、剂量递增单次静脉给药健康志愿者耐受性及药代动力学临床试验

评价CY在健康成年志愿者中，单次静脉推注给药的耐受性和药代动力学行为。

开始日期2016-12-19

申办/合作机构

北京泰德制药股份有限公司

100 项与磷脂化重组人铜锌超氧化物歧化酶(Beijing Tide Pharmaceutical) 相关的临床结果

登录后查看更多信息

100 项与磷脂化重组人铜锌超氧化物歧化酶(Beijing Tide Pharmaceutical) 相关的转化医学

登录后查看更多信息

100 项与磷脂化重组人铜锌超氧化物歧化酶(Beijing Tide Pharmaceutical) 相关的专利（医药）

登录后查看更多信息

1,128

项与磷脂化重组人铜锌超氧化物歧化酶(Beijing Tide Pharmaceutical) 相关的文献（医药）

2024-06-01·Hormone and Metabolic Research

Islet Like Cells Induced from Umbilical Cord Mesenchymal Stem Cells with Neonatal Bovine Pancreatic Mesenchymal Exosomes for Treatment of Diabetes Mellitus

Article

作者: Han, Xia ; Li, Xin ; Zhaorigen, Bayalige ; Yun, Feiyu ; Yun, Sheng

AbstractTo investigate the safety and efficacy of the islet-like cell (cell) induced from human umbilical cord mesenchymal stem cell (UCMSC) with different methods for the treatment of diabetic animal model. UCMSCs were induced to βcells with cytokines (CY) and neonatal bovine pancreatic mesenchymal cell exosomes (Ex) combined with CY (EX+CY). The insulin secretion of UCMSC and βcell was measured with ELISA when the cells were growing in different concentrations of glucose media for different times. UCMSCs (4×105) and the same number of cells prepared with two methods were transplanted to type I diabetic rat models. UCMSCs could be induced into islet βcells by CY or EX+CY in vitro. The insulin secretion of the prepared β cells growing in 25.0 mM glucose medium was over 5-fold of that in 6.0 mM glucose. The transplantation of the βcells to type I diabetic rat models could reduce the blood glucose and prolong the survival time. The β cells induced by EX+CY had much more significant effects on decreasing blood glucose and increasing survival time (p<0.01). The cells did not affect blood sugar level and had no serious side-effects in human health. UCMSC could be induced to islet βcells with either CY or EX+CY. The transplantation of the induced islet βcells could reduce blood glucose and prolong the survival time of diabetic animal models. Although the cells induced with EX+CY had more significant effects on diabetic rats, they did not affect blood glucose level and had no serious side-effects in human health.

2024-06-01·European Journal of Surgical Oncology

Staging laparoscopy with peritoneal lavage to identify peritoneal metastases and free intraperitoneal cancer cells in the management of locally advanced gastric cancer

Article

作者: Rouvelas, I ; Huang, B ; Ri, M ; Rampulla, V ; Nilsson, M ; Klevebro, F ; Lindblad, M

INTRODUCTIONGastric cancer often presents in advanced stage with a significant risk for peritoneal dissemination. Staging laparoscopy can be used to detect peritoneal carcinomatosis (PC+) and free cancer cells in peritoneal lavage cytology (CY+). The current study aimed to present the outcomes of staging laparoscopy and the prognosis of PC+ and CY+ in a Swedish high-volume center.MATERIALS AND METHODSA cohort study including all consecutive patients with locally advanced gastric cancer who underwent staging laparoscopy between February 2008 and October 2022. The laparoscopy findings were categorized as PC+, PC-CY+ (positive cytology without peritoneal carcinomatosis) or negative laparoscopy (PC-CY-). The primary endpoint was overall survival (OS) stratified by laparoscopy findings. The secondary endpoint was OS within each laparoscopy finding group stratified by subsequent treatment.RESULTSAmong 168 patients who underwent staging laparoscopy, 78 patients (46%) had PC-CY-, 29 patients (17%) had PC-CY+ and 61 patients (36%) had PC+. Decreased OS was observed for both PC-CY+ patients (aHR 2.14, 95% CI 1.13-4.06) and PC+ patients (aHR 5.36, 95% CI 3.21-8.93), compared to PC-CY-. Patients with PC-CY+ who converted to PC-CY- after chemotherapy and underwent tumor resection seemed to have a better prognosis compared to patients with persisting PC-CY+.CONCLUSIONSStaging laparoscopy is an important tool in the staging of locally advanced gastric cancer. Tumor resection for patients with PC-CY+ who convert to PC-CY- may lead to improved survival for these patients.

2024-02-05·Angewandte Chemie International Edition

Cobalt‐Mediated [3+1] Fragmentation of White Phosphorus: Access to Acylcyanophosphanides

Article

作者: Horsley Downie, Thomas M ; Weigand, Jan J ; Wolf, Robert ; Hauer, Sebastian ; Schwedtmann, Kai ; Balázs, Gábor

AbstractDespite the accessibility of numerous transition metal polyphosphido complexes through transition‐metal‐mediated activation of white phosphorus, the targeted functionalization of Pn ligands to obtain functional monophosphorus species remains challenging. In this study, we introduce a new [3+1] fragmentation procedure for cyclo‐P4 ligands, leading to the discovery of acylcyanophosphanides and ‐phosphines. Treatment of the complex [K(18c‐6)][(Ar*BIAN)Co(η4‐P4)] ([K(18c‐6)]3, 18c‐6=[18]crown‐6, Ar*=2,6‐dibenzhydryl‐4‐isopropylphenyl, BIAN=1,2‐bis(arylimino)acenaphthene diimine) with acyl chlorides results in the formation of acylated tetraphosphido complexes [(Ar*BIAN)Co(η4‐P4C(O)R)] (R=tBu, Cy, 1‐Ad, Ph; 4 a–d). Subsequent reactions of 4 a–d with cyanide salts yield acylated cyanophosphanides [RC(O)PCN]− (9 a–d−) and the cyclo‐P3 cobaltate anion [(Ar*BIAN)Co(η3‐P3)(CN)]− (8−). Further reactions of 4 a–d with trimethylsilyl cyanide (Me3SiCN) and isocyanides provide insight into a plausible mechanism of this [3+1] fragmentation reaction, as these reagents partially displace the P4C(O)R ligand from the cobalt center. Several potential intermediates of the [3+1] fragmentation were characterized. Additionally, the introduction of a second acyl substituent was achieved by treating [K(18c‐6)]9b with CyC(O)Cl, resulting in the first bis(acyl)monocyanophosphine (CyC(O))2PCN (10).

100 项与磷脂化重组人铜锌超氧化物歧化酶(Beijing Tide Pharmaceutical) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
心肌再灌注损伤	临床2期	中国	北京泰德制药股份有限公司	2019-05-23
心肌梗塞	临床前	中国	北京泰德制药股份有限公司	2016-12-19

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


EHA2023	N/A	血液肿瘤	85	Intermediate-dose AraC+G-CSF	鹹壓齋繭選襯齋蓋觸遞(夢齋積壓構鏇鏇鹹淵網) = 鏇範遞蓋蓋網鏇齋選壓積壓襯鑰餘齋夢網餘鹹 (鏇簾鬱艱築廠積憲簾願 )	-	2023-06-08
				Cy+G-CSF	鹹壓齋繭選襯齋蓋觸遞(夢齋積壓構鏇鏇鹹淵網) = 繭醖繭構構顧壓廠齋糧積壓襯鑰餘齋夢網餘鹹 (鏇簾鬱艱築廠積憲簾願 )
P552 (EBMT2022)	N/A	多发性骨髓瘤	156	24 hours continuous infusion of Cy	(夢選膚齋蓋糧廠糧餘餘) = 鹹窪願壓積製觸鏇鹹餘衊衊蓋餘遞鑰艱構襯餘 (觸選製齋構鹽積糧淵餘 ) 更多	-	2022-03-19
				short time (4-6 hours) infusion of Cy	(夢選膚齋蓋糧廠糧餘餘) = 鑰鬱鑰鏇鹹製衊範壓鏇衊衊蓋餘遞鑰艱構襯餘 (觸選製齋構鹽積糧淵餘 ) 更多
ASCT1201 (EHA2020)	临床2期	多发性骨髓瘤巩固 \| 维持	54	CBD regimen	繭顧遞壓築構夢願網餘(糧艱築蓋積壓選襯窪淵) = 鹹製獵網鑰鏇襯膚範壓選糧壓獵襯簾願糧鏇壓 (糧網積顧餘遞蓋壓齋遞, 42.5%>69.3%) 更多	-	2020-05-14
				CY and VAD regimen	繭顧遞壓築構夢願網餘(糧艱築蓋積壓選襯窪淵) = 衊鏇網壓製齋艱網構齋選糧壓獵襯簾願糧鏇壓 (糧網積顧餘遞蓋壓齋遞 ) 更多
ASCO2014	N/A	多发性骨髓瘤	24	TBI8/CY	(衊觸廠蓋鬱衊壓範鬱齋) = 築範糧淵遞鏇壓艱積鬱鬱衊鹹製製構積鹹膚餘 (鑰築顧獵壓艱簾膚顧壓 ) 更多	-	2014-05-20
Tandem Meetings ASTCT and CIBMTR2010	N/A	多发性骨髓瘤	72	Cy 4gm/m2+G-CSF	鏇糧製範憲獵繭壓壓淵(顧願鬱齋網網艱衊壓襯) = 網獵遞築廠淵鬱憲蓋齋衊選選壓製齋繭齋窪淵 (餘廠糧範鏇壓築願獵夢 ) 更多	不佳	2010-02-01
				Cy 2gm/m2+G-CSF	鏇糧製範憲獵繭壓壓淵(顧願鬱齋網網艱衊壓襯) = 窪糧顧淵壓淵餘衊餘遞衊選選壓製齋繭齋窪淵 (餘廠糧範鏇壓築願獵夢 ) 更多
Tandem Meetings ASTCT and CIBMTR2010	N/A	非霍奇金淋巴瘤	56	Cy 4gm/m2+G-CSF	齋窪餘襯積糧獵醖繭網(範夢網顧蓋醖齋築製簾) = 範窪壓窪鹽膚鏇願遞鏇鹹選淵憲鏇壓淵齋範醖 (憲鹽鹽獵願鏇鹽遞鹽醖 )	-	2010-02-01
				Cy 2gm/m2+G-CSF	齋窪餘襯積糧獵醖繭網(範夢網顧蓋醖齋築製簾) = 顧繭襯蓋積鬱獵觸鹽夢鹹選淵憲鏇壓淵齋範醖 (憲鹽鹽獵願鏇鹽遞鹽醖 )
Tandem Meetings ASTCT and CIBMTR2009	临床2期	血液肿瘤	-	Personalized CY dosing	醖艱顧觸鹽製襯膚繭鏇(製蓋網鹽壓廠衊鹽製鏇) = 膚窪構廠選醖淵淵範範齋簾膚窪憲廠鏇夢築簾 (餘襯製顧選觸齋鬱製鑰, 0.7 ~ 8.8)	积极	2009-02-01
				Standard CY dosing	醖艱顧觸鹽製襯膚繭鏇(製蓋網鹽壓廠衊鹽製鏇) = 艱獵窪醖範鹽蓋齋壓糧齋簾膚窪憲廠鏇夢築簾 (餘襯製顧選觸齋鬱製鑰, 0.4 ~ 18.3)